Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier January 13, 2014 | By Michael Gibney
Crossing the blood-brain barrier is notoriously one of the most difficult challenges in drug delivery. But overcoming that obstacle can have vast implications for the treatment of high-profile market areas such as Alzheimer's, Huntington's and brain cancer. Now researchers at Roche ($RHHBY) have developed an antibody-based technique to "shuttle" large molecules into the brain, increasing exposure to the drug.
For Alzheimer's drugs in particular, which have suffered several big flops recently in later stages, this type of back-to-the-basics kind of research could begin a new, more successful wave.
Roche scientists published a study in the journal Neuron demonstrating that their method using a natural protein transport mechanism called the transferrin receptor pathway helped get Roche's experimental antibody gantenerumab into the brain to reduce amyloid plaque, thought to be a contributor to Alzheimer's disease.
Crossing the blood-brain barrier is notoriously difficult, but overcoming that obstacle can have vast implications for the treatment of Alzheimer's, Huntington's and brain cancer. Now researchers at Roche have developed an antibody-based technique to "shuttle" large molecules into the brain ...
Roche scientists published a study in the journal Neuron demonstrating that their method using a natural protein transport mechanism called the transferrin receptor pathway helped get Roche's experimental antibody gantenerumab into the brain to reduce amyloid plaque, thought to be a contributor to Alzheimer's disease.
na für ne Zockeraktie eigentlich zu teuer. Aber vielleicht kommen wir ja mal wieder in ruhigeres Fahrwasser. Die Richtung stimmt heute auf alle Fälle. Mal schauen wann die 70 erreicht sind.
Ich schätze ihr sitzt alle gebannt vor dem Bildschirm und wartet, dass die 70 geknackt werden und endlich die 80, auch ohne Übernahme, auf dem Radar erscheint.